APR 246

Drug Profile

APR 246

Alternative Names: APR-246; PRIMA-1-MET; UNII-Z41TGB4080

Latest Information Update: 27 Mar 2017

Price : $50

At a glance

  • Originator Aprea
  • Class Antineoplastics; Quinuclidines; Small molecules
  • Mechanism of Action Tumour suppressor protein p53 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer; Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Ovarian cancer
  • Preclinical Lung cancer; Oesophageal cancer
  • No development reported Haematological malignancies; Prostate cancer

Most Recent Events

  • 22 Mar 2017 Aprea Therapeutics and Memorial Sloan Kettering Cancer Center collaborate on Cancer for APR 246
  • 09 Mar 2017 H. Lee Moffitt Cancer Center and Research Institute plans a phase I/II trial for Haematological malignancies (Combination therapy) in USA (NCT03072043)
  • 20 Dec 2016 Peter MacCallum Cancer Centre, Australia plans the phase Ib/II APROC trial for Oesophageal cancer (Combination therapy, Second-line therapy or greater, Late-stage disease, Metastatic disease) in Australia (IV) (NCT02999893)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top